[go: up one dir, main page]

FR2778851B1 - Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes - Google Patents

Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes

Info

Publication number
FR2778851B1
FR2778851B1 FR9806288A FR9806288A FR2778851B1 FR 2778851 B1 FR2778851 B1 FR 2778851B1 FR 9806288 A FR9806288 A FR 9806288A FR 9806288 A FR9806288 A FR 9806288A FR 2778851 B1 FR2778851 B1 FR 2778851B1
Authority
FR
France
Prior art keywords
hemolysis
erythrocytes
destruction
self
protease inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9806288A
Other languages
English (en)
Other versions
FR2778851A1 (fr
Inventor
Jean Claude Ameisen
Daniela Bratosin
Jerome Estaquier
Jean Jacques Huart
Jean Montreuil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AETSRN
Association pour lEssor de la Transfusion Sanguine dans la Region Nord
Original Assignee
AETSRN
Association pour lEssor de la Transfusion Sanguine dans la Region Nord
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AETSRN, Association pour lEssor de la Transfusion Sanguine dans la Region Nord filed Critical AETSRN
Priority to FR9806288A priority Critical patent/FR2778851B1/fr
Publication of FR2778851A1 publication Critical patent/FR2778851A1/fr
Application granted granted Critical
Publication of FR2778851B1 publication Critical patent/FR2778851B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9806288A 1998-05-19 1998-05-19 Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes Expired - Fee Related FR2778851B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9806288A FR2778851B1 (fr) 1998-05-19 1998-05-19 Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9806288A FR2778851B1 (fr) 1998-05-19 1998-05-19 Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes

Publications (2)

Publication Number Publication Date
FR2778851A1 FR2778851A1 (fr) 1999-11-26
FR2778851B1 true FR2778851B1 (fr) 2002-07-26

Family

ID=9526488

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9806288A Expired - Fee Related FR2778851B1 (fr) 1998-05-19 1998-05-19 Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes

Country Status (1)

Country Link
FR (1) FR2778851B1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11243218B2 (en) 2015-10-07 2022-02-08 Sangui Bio Pty Ltd. Blood preparation and profiling
US11693006B2 (en) 2016-12-20 2023-07-04 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016374643B2 (en) * 2015-12-22 2023-12-14 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815962D0 (en) * 1988-07-05 1988-08-10 Univ London Pharmaceutical preparation & method for promoting reinnervation of muscle fibers
US5736520A (en) * 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
WO1991008769A1 (fr) * 1989-12-18 1991-06-27 Transgene S.A. Composition pharmaceutique destinee au traitement ou a la prevention des infections retrovirales
EP0580161A1 (fr) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Traitement prophylactique et thérapeutique de la maladie d'Alzheimer
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11243218B2 (en) 2015-10-07 2022-02-08 Sangui Bio Pty Ltd. Blood preparation and profiling
US11693006B2 (en) 2016-12-20 2023-07-04 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors

Also Published As

Publication number Publication date
FR2778851A1 (fr) 1999-11-26

Similar Documents

Publication Publication Date Title
DZ2285A1 (fr) Inhibiteurs de protéase de la cystéine.
ZA951573B (en) Cysteine protease inhibitors
HUP0103283A3 (en) Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds
PT1086076E (pt) Inibidores de sulfonamida de aspartil protease
GB9917909D0 (en) Cysteine protease inhibitors
EP0923535A4 (fr) Inhibiteurs de cysteine protease
DK1077681T3 (da) Levothyroxin-natriumholdigt farmaceutisk præparat
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
IL139187A0 (en) Cysteine protease inhibitors
AU2003301857A1 (en) New process for the preparation of racemic ((2s(2r*(r(r*)))) and ((2r(2s*(s(s*))))-(plus or minus)- alpha,alpha' -(imino-bis(methylene))bis(6-fluoro-chroman-2-methanol) and its pure (2s(2r*(r(r*)and
IS5531A (is) Grindarmálmpróteasa latar
FR2778851B1 (fr) Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes
NO20011388D0 (no) Hydroksamat-inneholdende cystein- og serinproteasehemmere
ATE273307T1 (de) Benzo(5,6)cycloheptapyridin derivate anwendbar als farnesyl protein transferase inhibitoren
ID24267A (id) Enansiomer-enansiomer dari 4-[[(sianoimino) [(1,2,2-trimetilpropil) amino] metil] amino] benzonitril
WO2002024727A3 (fr) Nouveaux inhibiteurs de la formation de fibrilles d'iapp et utilisations associees
ITBO990185A0 (it) Metodo per la determinazione della funzionalita' mitocondriale e relat ivo kit .
DK0906309T3 (da) Modificeret form af R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotinsyre-hydrochloridet
IL155961A0 (en) Cysteine protease inhibitors
DE69930852D1 (de) Prenyltransferase-inhibitoren
FR2787309B3 (fr) Dispositif destine au port des chaussures
UA2779S (uk) Комплект етикеток "золотий келих"
ITRM20000686A0 (it) Apparato per la misura della planarita' di superfici, in particolare nastri metallici.
ZA969078B (en) Inhibitors of cysteine protease.
FR2821431B1 (fr) Reactif destine au depistage ante-morten d'atnc

Legal Events

Date Code Title Description
CL Concession to grant licences
TP Transmission of property
ST Notification of lapse

Effective date: 20140131